179 related articles for article (PubMed ID: 3519004)
1. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
St-Arnaud R; Lachance R; Kelly SJ; Belanger A; Dupont A; Labrie F
Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
[TBL] [Abstract][Full Text] [Related]
2. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
St-Arnaud R; Lachance R; Dupont A; Labrie F
Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
[TBL] [Abstract][Full Text] [Related]
4. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of flutamide action on prostatic and testicular functions in the rat.
Marchetti B; Labrie F
J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
[TBL] [Abstract][Full Text] [Related]
6. The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole.
Lacoste D; St-Arnaud R; Caron S; Belanger A; Labrie F
J Steroid Biochem; 1988 Dec; 31(6):963-70. PubMed ID: 3059065
[TBL] [Abstract][Full Text] [Related]
7. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
Labrie F; Dupont A; Belanger A; Lachance R
J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
[TBL] [Abstract][Full Text] [Related]
8. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
Lacoste D; Dubé D; Bélanger A; Labrie F
Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
[TBL] [Abstract][Full Text] [Related]
9. A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog.
Lacoste D; St-Arnaud R; Bélanger A; Labrie F
Mol Cell Endocrinol; 1988 Mar; 56(1-2):141-7. PubMed ID: 3286322
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Redding TW; Schally AV
Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
[TBL] [Abstract][Full Text] [Related]
11. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
Roman SH; Goldstein M; Kourides IA; Comite F; Bardin CW; Krieger DT
J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
[TBL] [Abstract][Full Text] [Related]
12. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Labrie F; Dupont A; Belanger A; Lachance R; Giguere M
Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
[TBL] [Abstract][Full Text] [Related]
14. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
[TBL] [Abstract][Full Text] [Related]
16. Effect of 3-week treatment with [D-Trp6, des-Gly-NH10(2)]LHRH ethylamide, aminoglutethimide, ketoconazole or flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog.
Lacoste D; Caron S; Bélanger A; Labrie F
J Steroid Biochem; 1989 Aug; 33(2):233-42. PubMed ID: 2671505
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
[TBL] [Abstract][Full Text] [Related]
18. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.
Bélanger A; Giasson M; Couture J; Dupont A; Cusan L; Labrie F
Prostate; 1988; 12(1):79-84. PubMed ID: 3279409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]